Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma Side Effects- Cardiovascular, Thromboembolic Mortality Risk

Share Button

The 4 cardiovascular and thromboembolic diseases resulting in death in patients with MM were atherosclerosis (n = 88), heart disease (n = 3799), aortic aneurysm and dissection (n = 39), and cerebrovascular disease (n = 1861).

Wow. Cardiovascular and thromboembolic diseases seem to be almost as deadly as myeloma itself. What the article linked and excerpted below doesn’t say is that the 4 cardiovascular and thromboembolic diseases discussed are caused by chemotherapy and radiation given to treat the patient’s myeloma! The mortality risk discussed in the article below are multiple myeloma side effects.

I’m assuming that if you’re reading this post then you are a MM patient, survivor or caregiver who is interested in managing or healing possible treatment-related cardiovascular and thromboembolic diseases.

Let me set the stage by saying that I was diagnosed with MM in early 1994. I developed two DVT’s during my induction therapy from 4/95-8/95. I then developed chronic a-fib in 2010. I’m not sure when it developed but I’ve been managing an aortic anerysm while I manage my a-fib. I was given a diagnosis of chemotherapy-induced cardiomyopathy in early 2019.

I am the poster child for cardiovascular and thromboembolic diseases.

All to say that that I could be one of the statistics described below (mortality…) any time now. It’s been more than 25 years since my MM diagnosed and the administration of the cardiotoxic chemo that gave me the cardiovascular and thromboembolic diseases that I am writing about.

So, by living with all these health challenges and not dying,  am I just lucky or am I doing something right? I think I’m doing lots of things right aka keeping me alive and MM free. The more time that passes since I was diagnosed and given all those toxic therapies, the stronger the case I can make for doing something right.

  • Anti-MM nutrition
  • Anti-MM supplementation
  • Anti-MM lifestyle therapies
  • Mind-body therapies

and more.

Are you a MM survivor? Did you undergo cardiotoxic chemotherapy regimens such as V.A.D, cytoxan, busulfan, melphalan, carfilsomib, others? Scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Cardiovascular, Thromboembolic Mortality Risk Factors in Multiple Myeloma

“In patients with multiple myeloma (MM), gender, age, marital status, tumor grade, and surgery were significant risk factors for death via thromboembolic and cardiovascular diseases, according to results from a population-based study presented recently at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia.

Patients with MM are at a higher risk for cardiovascular and thromboembolic events, so researchers used the Surveillance, Epidemiology, and End Results (SEER) database to assess data from 55,991 patients with multiple myeloma to analyze cardiovascular and thromboembolic mortality risk in these patients. A total of 4510 deaths by cardiovascular and thromboembolic events occurred.

Analyses revealed the hazard ratio (HR) for death via thromboembolic and cardiovascular diseases as a patient with MM was 1.39 for male patients (P =.005), 1.07 for increased age (P =.005), and 0.81 for being married (P =.0014). Tumor grade and surgery were also significant risk factors for death.

The 4 cardiovascular and thromboembolic diseases resulting in death in patients with MM were atherosclerosis (n = 88), heart disease (n = 3799), aortic aneurysm and dissection (n = 39), and cerebrovascular disease (n = 1861). In addition, the higher the grade of MM, the lower the survival probability (P <.001).

Patients with hypertension and MM experienced the best median survival, and patients with aortic aneurysm and MM experienced the worst median survival.

The researchers noted that additional research is needed, particularly to identify patients who could benefit most from cardiovascular and thromboembolic prophylaxis.


Elfaituri MK, Morsy S, El-Qushayri AE, et al. Cardiovascular and thromboembolic diseases as a cause of death in multiple myeloma patients: a population based study. Poster presented at: American Association for Cancer Research 2019 Annual Meeting; March 29-April 3, 2019; Atlanta, GA. Abstract 3302/22.

“Conclusion: The mortality from by cardiovascular and thromboembolic events in MM was associated with several factors. Our considerations and further investigations of them is needful. It may aid in identifying the patients who can get the uppermost benefits of cardiovascular and thromboembolic prophylaxis and treatment measures.”

Leave a Comment: